Beijing SL Pharmaceutical Co (SZSE:002038) Net Income (Continuing Operations) : ¥81.0 Mil (TTM As of Sep. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Beijing SL Pharmaceutical Co Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Beijing SL Pharmaceutical Co's Net Income (Continuing Operations) for the three months ended in Sep. 2024 was ¥-46.5 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Sep. 2024 was ¥81.0 Mil.

Beijing SL Pharmaceutical Co Net Income (Continuing Operations) Historical Data

The historical data trend for Beijing SL Pharmaceutical Co's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing SL Pharmaceutical Co Net Income (Continuing Operations) Chart

Beijing SL Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income (Continuing Operations)

Get a 7-Day Free Trial

479.50

361.45

421.33

228.34

414.96

Beijing SL Pharmaceutical Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Net Income (Continuing Operations)	Get a 7-Day Free Trial															0.05	98.73	69.68	-40.89	-46.53

Beijing SL Pharmaceutical Co Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥81.0 Mil.

Beijing SL Pharmaceutical Co (SZSE:002038) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Beijing SL Pharmaceutical Co Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Beijing SL Pharmaceutical Co's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing SL Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beijing SL Pharmaceutical Co Ltd (SZSE:002038) » Definitions » Net Income (Continuing Operations)

Traded in Other Exchanges

N/A

Address

No.69 Fu shi Road, No.1 Building, Bitongyuan, Haidian district, Beijing, CHN, 100049

Website

http://www.slpharm.com.cn

Beijing SL Pharmaceutical Co Ltd is a Chinese biotechnology-pharmaceutical company. It is principally focused on developing and marketing gene engineering drugs. The product portfolio of the company includes drugs for Oncology, Hepatopathy and Senile disease. Its products include Filgrastim, Asparaginase, Dasartinib, Enoxaparin, Naftopidil, Ademetionine, Lenalidomide, and others.

Executives

Liang Shu Jie	Secretary, Director
Xu Ming Bo	Directors, executives
Yang Zhong Fan	Supervisors
Chen Yu Lin	Director
Qi Yan Ming	Supervisors
Xi Wen Ying	Executives
Wu Yan Zhuo	Executives
Wang Wen Xin	Director
Li Ya Jun	Executives
Zhao Xia	Securities Affairs Representative
Zhang Chun Lei	Supervisors
Wang Yong Bo	Directors, executives
Lu An Jing	Supervisors
Wei Su Yan	Director

Beijing SL Pharmaceutical Co Headlines

No Headlines